Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "Gackstroemia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor
InactiveUS7479371B2Biological material analysisImmunoglobulins against growth factorsGackstroemiaPreleukemia
Owner:TOKAI UNIV +2
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof
ActiveUS9822181B2Extended half-lifeAntipyreticAntibody mimetics/scaffoldsGackstroemiaHematologic malignancy
Owner:MACROGENICS INC
Cell differentiation inducer
The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Cell differentiation inducer
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Non-lethal methods for conditioning a recipient for bone marrow transplantation
InactiveUS6217867B1Reduce proliferationDiminished cytotoxic activityBiocideOrganic active ingredientsGackstroemiaAcquired immunodeficiency
The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.
Owner:PITTSBURGH UNIV OF
Nitrate medicament for inhibiting angiogenesis
The invention provides a nitrate medicament for inhibiting angiogenesis. The general formula (I) of the medicament is T-(B-M)t1, wherein t1 is 1 or 2, T-Ht1 is a steroidal compound, and T-H means that oxygen atoms of the T are connected with the H to form the hydroxyl connection, namely the O-H typed connection. The compound of the formula (I) can be synthesized by taking the steroidal compound T-Ht1 as a raw material, and can be used for preparing the medicaments of treating angiogenesis diseases of human or mammals, particularly the medicaments of treating the diseases such as tumors, ocular angiogenesis, malignant blood diseases, bronchial asthma, leukoaraiosis and the like.
Owner:TIANJIN JINYAO GRP
Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof
ActiveUS20180244748A1Stimulate immune responsePeptide/protein ingredientsAntibody mimetics/scaffoldsDendritic cellGackstroemia
The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Non-lethal methods for conditioning a recipient for bone marrow transplantation
InactiveUS20030165475A1Diminished proliferative and cytotoxic activityDosage of TBI can be further reducedBiocideEnergy modified materialsAcquired immunodeficiencyGackstroemia
Owner:ILDSTAD SUZANNE T
Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Humanized Anti-human cd34 antibody, the preparation method and uses thereof
InactiveUS20100311955A1Reduce recurrenceReduce morbiditySugar derivativesImmunoglobulins against cell receptors/antigens/surface-determinantsGackstroemiaHumanized antibody
The present invention provides a humanized anti-human CD34 antibody and the preparation method thereof. The humanized anti-human CD34 antibody retains the affinity and specificity of its original murine-derived antibody. The antibody can be conjugated with magnetic nano materials to prepare immunomagnetic beads to screen marrow hemopoietic stem cells. It can effectively reduce the incidence rate of HAMA and improve the security of clinical transplantation of hemopoietic stem cells and can be used in treatment of certain malignant hematologic diseases and solid tumors.
Owner:SHANGHAI GUOJIAN BIO TECH INST
Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
InactiveUS20120148577A1Reduce transplant rejectionReduce rejectionBiocidePeptide/protein ingredientsGackstroemiaSickle cell anemia
A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Method for treating and diagnosing hematologic malignancies
ActiveUS9243052B2Avoid overactivationStrong cytotoxicityAnimal cellsCell receptors/surface-antigens/surface-determinantsGackstroemiaPD-L1
Owner:OLIVE DANIEL +2
Phosphatidylinositol-3-kinase inhibitor and application thereof
InactiveCN101849934AInduce apoptosisControl proliferationOrganic active ingredientsAntineoplastic agentsGackstroemiaAkt signalling
The invention discloses new application of a 2-(4-fluorophenyl)-3-nitro-8-O-ethyl-2-hydro-benzopyran compound, in particular application of the compound serving as phosphatidylinositol-3-kinase (PI3K) inhibitor. The PI3K inhibitor can inhibit PI3K and disturb a PI3K / AKT signal channel, has good treatment effect on multiple tumors, particularly malignant hematological diseases, can effectively control the propagation of tumor cells and induce the apoptosis thereof, and has the effect of inhibiting and treating the tumors; and meanwhile, the PI3K has low toxicity.
Owner:SUZHOU UNIV
Methods for the treatment of hematologic malignancies
InactiveUS20100226917A1Organic active ingredientsAntibody ingredientsGackstroemiaHematologic malignancy
The present invention discloses, in part, therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or B cell related tumors comprising the administration of a CHK1 inhibitor in combination with a B cell depleting antibody. The present invention further includes treating hematologic malignancies, including B cell lymphomas and leukemias, or B cell related tumors, which are resistant to cancer treatment comprising the administration of a CHK1 inhibitor.
Owner:ASTRAZENECA AB
Antibodies to ntb-a
ActiveUS20090181009A1Immunoglobulins against cell receptors/antigens/surface-determinantsFermentationDiseaseGackstroemia
Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.
Owner:ARCA BIOPHARMA
Deep sequencing of peripheral blood plasma DNA as a reliable test for confirming the diagnosis of myelodysplastic syndrome
ActiveUS20160130648A1Increase in bone marrow blastsBiocidePeptide/protein ingredientsGackstroemiaHematologic malignancy
Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.
Owner:NEOGENOMICS LAB
RNA INTERFERENCE MEDIATED INHIBITION OF GRB2 ASSOCIATED BINDING PROTEIN (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
InactiveUS20090093435A1Improves various propertyImprove the immunityOrganic active ingredientsSugar derivativesDiseaseGackstroemia
This invention relates to compounds, compositions, and methods useful for modulating associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of associated binding protein (GAB2) gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of GAB2 genes. The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease (leukemia), inflammatory diseases or conditions, allergic diseases or conditions, or proliferative diseases or conditions.
Owner:SIRNA THERAPEUTICS INC
Ship inhibitors and uses thereof
ActiveUS20130102577A1Additional componentEngraftment can be facilitatedOrganic active ingredientsBiocideLymphatic SpreadGackstroemia
The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) a method of inhibiting a SHIP1 protein in a cell; (iii) a method of selectively inhibiting a SHIP1 protein in a cell; (iv) a method for treating or preventing graft-versus-host disease (GVHD) in a recipient of an organ or tissue transplant; (v) a method of modulating SHIP activity in a cell expressing SHIP1 or SHIP2; (vi) a method of ex vivo or in vitro treatment of transplants; (vii) a method of inhibiting tumor growth and metastasis in a subject; (viii) a method of treating a hematologic malignancy in a subject; (ix) a method of inducing apoptosis of multiple myeloma cells; (x) a method of treating multiple myeloma in a subject; (xi) a method of inhibiting the proliferation of a human breast cancer cell; and (xii) a method of treating breast cancer in a subject.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1
Methods and Compositions for Treating Malignancies with Dendritic Cells
This invention provides methods and compositions for the treatment and / or prevention of cancer, including solid malignancies and hematologic malignancies. In particular, the present invention relates to immunotherapy using antigen-presenting cells loaded with tumor associated peptide antigens (TAPAs). If a subject expresses at least one tumor-associated antigen, the subject can be treated by antigen-presenting cells (e.g., dendritic cells) loaded with at least one tumor-associated peptide antigen derived from the tumor-associated antigen (s) expressed by the subject. This personalized immunotherapy induces or enhances immune responses to cells that express tumor-associated antigen(s).
Owner:KIROMIC
Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
ActiveUS20170247452A1Extended half-lifeImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsGackstroemiaHematologic malignancy
Owner:MACROGENICS INC
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.
Owner:IL YANG PHARMA CO LTD
Antibodies to NTB-A
Owner:ARCA BIOPHARMA
Methods and Compositions for the Detection and Treatment of Cancer involving miRNAs and miRNA Inhibitors and Targets
ActiveUS20130064810A1Modify stabilityModify cellularOrganic active ingredientsSugar derivativesAssayGackstroemia
The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists / antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +2
Standardized therapy management system used for hematological malignancy patients
InactiveCN103020778AImprove the ability to standardize treatment managementReduce work omissionsResourcesNODALDisease
A standardized therapy management system used for hematological malignancy patients comprises a data base, a recording module, an evaluation module and a statistics module. The standardized therapy management system used for hematological malignancy patients comprehensively records disease information of the patients; provides standardized therapy, evaluation procedure and examination and testing methods; and manages therapeutic evaluation time and reexamination time nodes of the patients in standardized mode. Doctors can improve the capability of clinician standardized therapy management through the statistics module, work omissions caused by inadequate experience and negligence can be reduced, and state, curative effect and prognoses of the hematological malignancy patients can be evaluated through the evaluation module.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Ligands of hvem for treating hematologic malignancies and autoimmune diseases
ActiveUS20100196386A1Low immunogenicityStrong cytotoxicityNervous disorderPeptide/protein ingredientsChronic lymphatic leukemiaGackstroemia
The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.
Owner:OLIVE +1
Primer and method for detecting EZH2 genes
InactiveCN104862407AGood amplification efficiencyThere will be no missed detectionMicrobiological testing/measurementDNA/RNA fragmentationGackstroemiaSyndrome patient
The invention discloses a primer and method for detecting bone marrow hyperplasia exceptional syndromes, particularly for EZH2 gene mutation of exceptional syndrome patients. The method comprises the following steps: (i) amplifying the primer of the sequence of the 7th, 8th and 17th exons of EZH2 genes; adopting a Sanger sequencing technique and a sequencing primer. The primer and method, disclosed by the invention, can quickly detect the mutation of the 7th, 8th and 17th exons of EZH2 genes in a patient with a bone marrow hyperplasia exceptional syndrome; the detecting results are accurate, and can provide poor prognosis indices for myeloid malignant hematonosis (including MDS).
Owner:SHANGHAI ADICON CLINICAL LAB LNC
Ligands of HVEM for treating hematologic malignancies
ActiveUS8318166B2Strong cytotoxicityImprove rendering capabilitiesNervous disorderPeptide/protein ingredientsDiseaseGackstroemia
Owner:OLIVE +1
Construction expression of fusion gene carrier and its application
InactiveCN1757736ALow costLower medical costsPeptide/protein ingredientsAntineoplastic agentsGackstroemiaReverse transcriptase
A human telomerase reverse-transcriptase (hTERT) / human interleukin 18 (hIL 18) fusion protein with composite function is prepared from 2 cell factors with similar or complementary functions through artificial reforming of their linking terminals and configuring. The expression of its carrier is created for increasing its target killing power to tumor cells and the dendritic cell mediated immune-effect. It can be used to prepare the dendritic cell vaccine for treating cancer.
Owner:ZHEJIANG UNIV
Compositions and methods for treating hematologic malignancies and multiple drug resistance
InactiveUS7105656B2Cell receptors/surface-antigens/surface-determinantsSugar derivativesGackstroemiaHematologic malignancy
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Fusion gene vector construction and expression as well as uses
InactiveCN1995356ALow costLower medical costsGenetic material ingredientsFermentationGackstroemiaWhite blood cell
The invention discloses a cell factor fusing protein of human terminal-enzyme reverse transcriptase (hTERT) / human leucocyte 18(hIL18), which is characterized by the following: targeting tumour cell to kill; improving immune effect for dendritic cell; expanding tumour-proof scale; reducing medical cost obviously; providing the base of treating vaccine for tumour.
Owner:ZHEJIANG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com